Highlights
- •Confident data on demyelinating diseases is scarce in the Mexican healthcare system.
- •Multiple sclerosis and neuromyelitis were the most frequent conditions in Mexico.
- •CIS is undervalued in Mexico due to diagnosis and management issues.
- •Females were more prone to contracting a demyelinating disease.
- •Oral therapies are the most used second-line option for treating these conditions.
Abstract
Background
Demyelinating diseases (DD) are a group of chronic neurological diseases associated
with loss and injury of brain or spinal cord regions. These conditions could trigger
impairment of neurological functions and disability from earlier stages of life. Epidemiological
data on DD remains insufficient for decision-making in the Mexican healthcare system.
This study aims to describe the epidemiology of DD based on data from Mexico's National
Registry of Demyelinating Diseases.
Methods
A cross-sectional, registry-based, observational study was performed. We analyzed
408 reports of multiple sclerosis (331, 81%), neuromyelitis optica spectrum disorder
(67, 16%), chronic recurrent inflammatory optic neuropathy (5, 1%), clinically isolated
syndrome (4, 0.9%), and autoimmune encephalitis (1, 0.2%) reported across 2021.
Results
The time from first symptoms to diagnosis of any DD was about 3 years. A treatment
failure history was detected in 40% of patients. It was estimated that NMOSD accounts
for 20% of all disorders. There was evidence that the use of brand-name and generic
IFN drug products lead to increased therapeutic failures.
Conclusion
Our research team suggests reinforcing educational programs and activities based on
diagnosis and clinical management improvement to first-contact physicians and specialty
doctors and promoting awareness in the whole population.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Diagnostic delay of multiple sclerosis in a Portuguese population.Acta Med. Port. 2019; 32: 289-294https://doi.org/10.20344/AMP.11187
- First-line treatment failure: predictive factors in a cohort of 863 Relapsing-Remitting MS patients.Mult. Scler. Relat. Disord. 2021; 48https://doi.org/10.1016/J.MSARD.2020.102686
- Características clínicas y demográficas de los pacientes con esclerosis múltiple Clinical and demographic characteristics of patients with multiple sclerosis.Rev. Med. Inst. Mex. Seguro Soc. 2016; 54: S186-S190
- Quality governance in a pluralistic health system: Mexican experience and challenges.Lancet Glob. Health. 2018; 6: e1149-e1152https://doi.org/10.1016/S2214-109X(18)30321-8
- Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).J. Neurol. 2010; 257: 1500-1507https://doi.org/10.1007/S00415-010-5560-1
- Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990-2016.Acta Neurol. Belg. 2021; 121: 199-204https://doi.org/10.1007/S13760-020-01528-7
- Inflammatory demyelinating diseases of the central nervous system.Handb. Clin. Neurol. 2018; 145: 263-283https://doi.org/10.1016/B978-0-12-802395-2.00019-5
- Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.Drug Metab. Pharmacokinet. 2019; 34: 64-70https://doi.org/10.1016/J.DMPK.2018.11.004
- State-of-the-art review: demyelinating diseases in Indonesia.Mult. Scler. Int. 2021; 2021: 1-13https://doi.org/10.1155/2021/1278503
- IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.J. Exp. Med. 2005; 202: 473-477https://doi.org/10.1084/JEM.20050304
- Multiple sclerosis diagnosis delay and its associated factors among Iranian patients.Clin. Neurol. Neurosurg. 2020; 199https://doi.org/10.1016/J.CLINEURO.2020.106278
- Chronic relapsing inflammatory optic neuropathy (CRION).Curr. Opin. Ophthalmol. 2021; 32: 521-526https://doi.org/10.1097/ICU.0000000000000804
- Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India.Mult. Scler. 2014; 20: 1651-1653https://doi.org/10.1177/1352458514521503
- Editorial: epidemiology of atypical demyelinating diseases.Front. Neurol. 2021; 12662353https://doi.org/10.3389/FNEUR.2021.662353
- Clinical practice patterns in multiple sclerosis management: Mexican consensus recommendations.Mult. Scler. Relat. Disord. 2021; 53https://doi.org/10.1016/J.MSARD.2021.103053
- Accessibility to non-COVID health services in the world during the COVID-19 pandemic: review.Front. Public Health. 2021; 9https://doi.org/10.3389/FPUBH.2021.760795
- Multiple sclerosis in Mexico: a multicentre study.Rev. Neurol. 2003; 36: 1019-1022https://doi.org/10.33588/rn.3611.2002610
- Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition.Mult. Scler. 2020; 26: 1816-1821https://doi.org/10.1177/1352458520970841
Article info
Publication history
Published online: May 08, 2023
Accepted:
May 7,
2023
Received in revised form:
April 20,
2023
Received:
November 28,
2022
Identification
Copyright
© 2023 Elsevier B.V. All rights reserved.
